Dayvigo and Bupropion Interaction: What Clinicians and Patients Need to Know

How Lemborexant Is Metabolized, and Why CYP2D6 Does Not Matter Here

Lemborexant's metabolism depends almost entirely on CYP3A4, not CYP2D6. That single fact is the foundation for assessing this drug pair correctly.

The FDA-approved prescribing information for Dayvigo specifies that lemborexant is primarily metabolized by CYP3A4, with CYP3A5 contributing a minor fraction. [1] In a dedicated drug-interaction study, co-administration with itraconazole (a strong CYP3A4 inhibitor) increased lemborexant AUC by approximately 4-fold, triggering a label contraindication against strong CYP3A4 inhibitors and a dose-reduction recommendation to 5 mg maximum when moderate CYP3A4 inhibitors (for example, fluconazole or diltiazem) are used. [1]

Bupropion is not a CYP3A4 inhibitor at any clinically relevant dose. Its inhibitory fingerprint is at CYP2D6, where it acts as a moderate inhibitor with a K(i) of approximately 0.5 micromolar in vitro. [2] Because lemborexant does not depend on CYP2D6 for its clearance, bupropion's inhibitory activity at that enzyme produces no meaningful change in lemborexant plasma exposure.

CYP3A4 vs. CYP2D6: A Practical Enzyme Map

CYP3A4 handles roughly 50% of all marketed drugs, while CYP2D6 handles approximately 25%. [3] A drug can be a potent inhibitor of one without touching the other. Bupropion falls squarely in the CYP2D6 column.

From a pharmacokinetic standpoint, then, co-prescribing bupropion with lemborexant does not require a dose adjustment of lemborexant for metabolic reasons. That contrasts sharply with prescribing, say, ketoconazole or clarithromycin alongside Dayvigo, both of which would require a label-mandated dose cap.

Bupropion's Own Metabolic Pathway

Bupropion is primarily a substrate of CYP2B6. [2] After oral dosing, it is hydroxylated to its active metabolite hydroxybupropion (also via CYP2B6) and further reduced to erythrohydrobupropion and threohydrobupropion via carbonyl-reductase enzymes. [2] Lemborexant has no known inhibitory activity at CYP2B6 or carbonyl-reductase, so it does not alter bupropion's steady-state concentrations either.

The pharmacokinetic lane is therefore clear in both directions.

Pharmacodynamic Interactions: Where the Real Clinical Concern Lives

Pharmacokinetics aside, the combination still requires attention at the pharmacodynamic level. Two separate mechanisms apply here.

Additive CNS Depression

Lemborexant is a dual orexin receptor antagonist (DORA). It blocks orexin-1 (OX1R) and orexin-2 (OX2R) receptors, suppressing the wake-promoting orexin/hypocretin signaling system to support sleep onset and maintenance. [1] The downstream effect includes sedation that can persist into the morning hours, particularly at the 10 mg dose.

Bupropion is primarily a norepinephrine-dopamine reuptake inhibitor (NDRI) and is not classically sedating. However, at therapeutic doses (150 to 450 mg daily), some patients report dizziness, agitation, or altered sleep architecture. [2] When a patient takes lemborexant at night and bupropion in the morning, the temporal separation reduces but does not eliminate the overlap of their CNS effects.

The SUNRISE-1 trial (N=291) demonstrated that lemborexant 10 mg produced statistically significant residual sedation and impaired next-morning driving performance (standard deviation of lateral position, SDLP: +2.6 cm vs. Placebo, P<0.001 at 9 hours post-dose). [4] Adding any agent that contributes to dizziness or postural instability during waking hours could compound fall risk, particularly in adults over 65.

Seizure Threshold Lowering: The Less-Discussed Risk

Bupropion lowers the seizure threshold in a dose-dependent manner. The prescribing information states that the incidence of seizures at 300 mg/day is approximately 0.1%, rising to 0.4% at 400 mg/day. [2] Above 450 mg/day, seizure risk rises sharply and that ceiling dose is a hard label limit.

Several CNS depressants, including benzodiazepines and alcohol, are known to reduce seizure risk; their withdrawal or dose reduction in a patient already on bupropion can precipitate seizure. Lemborexant is not a GABAergic agent, so it does not provide the same protection as a benzodiazepine withdrawal buffer. Still, any CNS drug added to a bupropion regimen should prompt a review of the patient's seizure history and current bupropion dose before initiation.

The FDA label for Wellbutrin XL states: "WELLBUTRIN XL is contraindicated in patients with a seizure disorder. The following conditions can also increase the risk of seizure: ... Use of concomitant medications that lower the seizure threshold." [2] Lemborexant is not listed explicitly as a seizure threshold-lowering agent; however, any clinician prescribing the combination should document the seizure-risk review.

Orexin System Pharmacology and Why It Matters for This Pair

Understanding the orexin system helps frame why DORAss like lemborexant are generally safer in antidepressant combinations than older hypnotics.

Orexin Receptors and Sleep Architecture

Orexin peptides (orexin-A and orexin-B) are produced exclusively in the lateral hypothalamus. [5] They project broadly to noradrenergic, serotonergic, histaminergic, and dopaminergic nuclei, sustaining arousal. Lemborexant competitively and reversibly blocks both OX1R and OX2R, with greater functional selectivity at OX2R at therapeutic doses. [1] This targeted mechanism avoids the broad CNS depression associated with benzodiazepine receptor agonists (BZRAs), which is why lemborexant does not carry the same abuse-potential or respiratory-depression warnings.

Why DORAss Are Preferred Over BZRAs in Antidepressant Co-therapy

Several antidepressants, including mirtazapine and tricyclics, have significant CNS-depressant overlap with BZRAs, making the combination potentially hazardous. Bupropion, being non-sedating and non-GABAergic, is actually one of the antidepressants with less pharmacodynamic collision risk alongside a DORA.

A 2022 network meta-analysis published in The Lancet (Qaseem et al., encompassing 154 RCTs and 44,890 participants) found that DORA-class drugs including suvorexant and lemborexant produced superior next-day functioning compared with benzodiazepines and Z-drugs. [6] That advantage is preserved when the co-medication is bupropion, rather than a sedating antidepressant.

Clinical Severity Classification of This Interaction

Drug-drug interaction databases classify this pair differently depending on the database queried. That inconsistency creates prescriber confusion.

The following decision framework can help clinicians grade the interaction and act accordingly:

Level 1 (Pharmacokinetic, CYP-mediated): No interaction. Bupropion inhibits CYP2D6; lemborexant depends on CYP3A4. No dose adjustment is warranted on pharmacokinetic grounds alone.

Level 2 (Pharmacodynamic, CNS depression): Minor to moderate. Lemborexant produces dose-dependent next-morning sedation. Bupropion is mildly activating but may cause dizziness or blurred vision in some patients. The combined effect on psychomotor function warrants a starting dose of lemborexant 5 mg rather than 10 mg in most patients initiating both drugs concurrently.

Level 3 (Pharmacodynamic, seizure threshold): Context-dependent. Patients with no seizure history on standard bupropion doses (150 to 300 mg XL daily) face minimal added seizure risk from lemborexant. Patients on higher bupropion doses (≥400 mg daily), with a personal or family history of seizure, or with concurrent electrolyte disturbances should have this risk explicitly documented and discussed.

Level 4 (Special populations): Escalated monitoring warranted. Elderly patients (≥65 years), patients with hepatic impairment (Child-Pugh B or C), and those taking additional CNS-active medications require more careful titration. The Dayvigo label already recommends a maximum dose of 5 mg in patients with moderate hepatic impairment. [1]

Dose Adjustment and Prescribing Recommendations

No regulatory authority or guideline body has issued a formal contraindication or mandatory dose-adjustment requirement for concurrent lemborexant and bupropion use.

Starting Doses When Combining

When initiating lemborexant in a patient already stable on bupropion, the recommended approach based on pharmacological principles is:

• Begin lemborexant at 5 mg taken immediately before bed. Reserve titration to 10 mg for patients who tolerate the 5 mg dose without residual morning sedation after at least 7 nights.
• The label maximum of 10 mg/night applies regardless. No dose of lemborexant exceeds that ceiling.
• If bupropion is being started in a patient already taking lemborexant 10 mg, consider whether down-titrating lemborexant to 5 mg is appropriate until CNS tolerability with bupropion is established.

Timing of Bupropion Dosing

Bupropion XL is typically dosed once in the morning. SR formulations are dosed twice daily, with the second dose ideally no later than mid-afternoon to avoid sleep disruption. [2] That timing means the peak bupropion plasma concentration (Tmax approximately 5 hours for XL formulation) occurs well before lemborexant is administered, which reduces pharmacodynamic overlap.

Lemborexant's Tmax is approximately 1 to 3 hours after oral administration, with a half-life of approximately 17 to 19 hours. [1] The plasma-concentration overlap between morning bupropion activity and next-day residual lemborexant is greatest in the first several hours after waking, particularly at the 10 mg dose.

Monitoring Parameters

Once the combination is prescribed, a structured monitoring approach reduces risk.

Short-Term Monitoring (First 2 to 4 Weeks)

• Ask patients directly about next-morning sedation, difficulty waking, impaired driving confidence, and falls.
• Reconfirm that lemborexant is taken only when ≥7 hours of sleep time is available before the patient must be alert.
• Assess for new or worsening CNS symptoms from bupropion (agitation, dizziness, tremor) that could compound impairment.

Long-Term Monitoring

• Periodically reassess whether both drugs are still necessary. Insomnia often responds to cognitive behavioral therapy for insomnia (CBT-I), and the American Academy of Sleep Medicine (AASM) recommends CBT-I as first-line treatment ahead of pharmacotherapy. [7] Successful CBT-I may allow lemborexant discontinuation while bupropion continues for depression or smoking cessation.
• At each bupropion dose increase (for example, from 150 mg to 300 mg XL), re-evaluate seizure risk and document.

Patient Counseling Points

Patients taking this combination need specific, actionable information rather than generic warnings.

Tell patients to take lemborexant immediately before bed with at least 7 hours before planned waking. They should not take bupropion at night if prescribed for depression; the morning dosing schedule maintains the temporal gap that reduces CNS overlap.

Patients should avoid alcohol entirely while taking lemborexant, as the SUNRISE-1 trial showed alcohol further worsens next-morning driving impairment. [4] Bupropion's own label advises minimizing alcohol use due to seizure risk. [2] Both instructions reinforce each other.

Patients starting bupropion for smoking cessation using the Zyban 150 mg SR twice-daily protocol should understand that the 7 to 12-week treatment course is finite. That time-limited nature may make it reasonable to temporarily lower lemborexant to 5 mg for the duration of bupropion use if the patient is already on 10 mg.

Falls counseling deserves explicit attention in adults over 60. The SUNRISE-2 trial (N=900) showed that lemborexant 5 mg and 10 mg both reduced wake after sleep onset significantly versus placebo (P<0.001 at week 6), confirming the drug's efficacy. [8] That efficacy benefit must be weighed against morning balance impairment in fall-prone patients.

Special Populations

Hepatic Impairment

Lemborexant AUC increases approximately 2-fold in moderate hepatic impairment (Child-Pugh B). [1] Bupropion clearance is also reduced in hepatic impairment; the label recommends a reduced frequency or dose in these patients. [2] Co-prescribing both drugs in a patient with Child-Pugh B or C liver disease requires careful attention to both labels independently, and lemborexant should not exceed 5 mg in moderate impairment.

Older Adults

Lemborexant was specifically studied in adults aged 60 to 88 in SUNRISE-2. Efficacy was maintained, and the adverse-event profile was consistent with the general adult population. [8] However, the American Geriatrics Society 2023 Beers Criteria caution against most hypnotics in older adults due to fall risk. [9] Bupropion is listed as a potentially inappropriate medication in older adults in the Beers Criteria due to its lowering of the seizure threshold and risk of neuropsychiatric adverse effects. [9] Combining two Beers-listed agents in a patient over 65 should be explicitly justified and documented.

Patients With Eating Disorders

Bupropion is contraindicated in patients with bulimia nervosa or anorexia nervosa due to a higher seizure incidence in clinical trials. [2] These conditions can also disrupt sleep, for which a clinician might consider lemborexant. The contraindication for bupropion applies regardless of the sleep agent; clinicians should screen for eating disorders before prescribing bupropion in any context.

Summary of the Interaction: A Direct Clinical Answer

Dayvigo and bupropion can be co-prescribed. No pharmacokinetic mechanism drives a clinically significant change in either drug's plasma concentration. The interaction that does exist is pharmacodynamic: bupropion's dose-dependent seizure risk and lemborexant's next-morning sedation must each be managed on their own terms, and together they create an indication for starting at the lower lemborexant dose (5 mg) and reviewing seizure history before the combination is initiated.

The FDA label for Dayvigo does not list bupropion as a contraindicated or restricted co-medication. [1] Clinicians should still document the rationale for co-prescribing, confirm adequate sleep opportunity, and schedule a 2-to-4-week follow-up visit to assess CNS tolerability after initiation.